Emergent BioSolutions (EBS) Non-Current Assets (2010 - 2026)
Emergent BioSolutions (EBS) posted Non-Current Assets of $450.8 million for Q2 2026, down 33.98% on a QoQ basis from $682.8 million in Q1 2026, and down 35.38% year-over-year from $697.6 million in Q2 2025.
Powered by 
Analysis
Emergent BioSolutions (EBS) Non-Current Assets (2010 - 2026) Analysis & Trends
Emergent BioSolutions has reported Non-Current Assets for 17 years, with the latest figure at $450.8 million in Q2 2026.
- On a quarterly basis, Non-Current Assets fell 35.38% year-over-year to $450.8 million in Q2 2026; TTM through Jun 2026 was $2.5 billion, a 18.53% decrease from a year earlier, with the FY2025 full-year figure at $656.1 million, down 17.05% from the prior year.
- Non-Current Assets was $450.8 million for Q2 2026 at Emergent BioSolutions, down from $682.8 million in the prior quarter.
- The five-year high for Non-Current Assets was $2.0 billion in Q4 2022, with the low at $450.8 million in Q2 2026.
- Average Non-Current Assets over 5 years is $1.1 billion, with a median of $990.1 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets grew 15.88% in 2022, then slumped 41.53% in 2023.
- Over 5 years, Non-Current Assets stood at $2.0 billion in 2022, then plunged by 41.53% to $1.1 billion in 2023, then plunged by 30.84% to $791.0 million in 2024, then fell by 17.05% to $656.1 million in 2025, then sank by 31.29% to $450.8 million in 2026.
- The last three Non-Current Assets figures came in at $450.8 million (Q2 2026), $682.8 million (Q1 2026), and $656.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.47 Bn | 628.71 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 467.46 Bn | 460.93 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 369.31 Bn | 362.22 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 269.03 Bn | 261.74 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Pfizer | 158.11 Bn | 146.71 Bn | 10.94 Bn | 159.77 Bn |
| 6 | Bristol Myers Squibb | 127.96 Bn | 116.89 Bn | 9.25 Bn | 59.06 Bn |
| 7 | Sanofi | 51.83 Bn | 44.86 Bn | 10.79 Bn | 113.37 Bn |
| 8 | BeOne Medicines | 41.33 Bn | 36.23 Bn | 1.53 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 41.30 Bn | 41.30 Bn | - | 294.93 Mn |
| 10 | Emergent BioSolutions | 335.50 Mn | 194.60 Mn | 137.20 Mn | 450.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 450.80 Mn |
| Mar 31, 2026 | 682.80 Mn |
| Dec 31, 2025 | 656.10 Mn |
| Sep 30, 2025 | 674.10 Mn |
| Jun 30, 2025 | 697.60 Mn |
| Mar 31, 2025 | 719.30 Mn |
| Dec 31, 2024 | 791.00 Mn |
| Sep 30, 2024 | 816.40 Mn |
| Jun 30, 2024 | 859.00 Mn |
| Mar 31, 2024 | 1.12 Bn |
| Dec 31, 2023 | 1.14 Bn |
| Sep 30, 2023 | 1.17 Bn |
| Jun 30, 2023 | 1.40 Bn |
| Mar 31, 2023 | 1.73 Bn |
| Dec 31, 2022 | 1.96 Bn |
| Sep 30, 2022 | 1.80 Bn |
| Jun 30, 2022 | 1.65 Bn |
| Mar 31, 2022 | 1.68 Bn |
| Dec 31, 2021 | 1.69 Bn |
| Sep 30, 2021 | 1.76 Bn |
API Access
Emergent BioSolutions Non-Current Assets API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=non-current-assets&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "non-current-assets", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=non-current-assets&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();